Zibotentan + dapagliflozin combination demonstrated significant albuminuria reduction in patients with chronic kidney disease and proteinuria in ZENITH-CKD Phase IIb trial
Combination of zibotentan with dapagliflozin showed statistically significant and clinically meaningful reductions in urinary albumin-to-creatinine ratio (UACR), used to assess albuminuria, at 12 weeks compared with dapagliflozin alone
After 12 weeks of treatment, the Phase IIb ZENITH-CKD trial showed that the UACR difference of zibotentan/dapagliflozin versus dapagliflozin alone (n=177) was –33.7% (90% CI –42.5 to –23.5; p<0.001) for high dose (1.5 mg zibotentan 10 mg dapagliflozin; n="179)" and –27.0% (90% ci –38.4 to –13.6; p="0.002)" for low dose (0.25 mg 10 mg; n="91)." the percentage mean change from baseline in uacr was –52.5% (90% ci –59.0 to –44.9) for high-dose and –47.7% (90% ci –55.7 to –38.2) for low-dose combination. these results were presented at the american society of nephrology (asn) kidney week 2023 and simultaneously published in the lancet.
Previous studies showed endothelin A (ETA) receptor antagonists are associated with high rates of fluid retention. The results from ZENITH-CKD showed low-dose zibotentan/dapagliflozin, but not high-dose, had comparable fluid retention events to dapagliflozin alone, with 18.4% (33/179), 8.8% (8/91) and 7.9% (14/177) of patients experiencing events in high-dose combination, low-dose combination and dapagliflozin groups, respectively.
Hiddo Heerspink, Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands, said: “Elevated levels of albuminuria are associated with an increased risk of kidney function loss over time and by reducing the level, we can lower the risk of progression to kidney failure. Today’s encouraging data from the ZENITH-CKD trial show therapeutic potential to help patients who remain at risk due to residual albuminuria by harnessing the beneficial aspects of an ETA receptor antagonist with an SGLT2 inhibitor.”
Sharon Barr, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, said “Despite current treatment options, residual proteinuria persists in a sizeable portion of patients and is associated with a high risk of kidney failure. The evidence published today supports advancement of zibotentan/dapagliflozin into a Phase III clinical trial to further assess its potential as a first-in-class treatment for residual proteinuria in CKD.”
See- "Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase IIb, clinical trial": Prof Hiddo J L Heerspink, PhD , Arihiro Kiyosue, PhD, Prof David C Wheeler, MD, Min Lin, PhD, Emma Wijkmark, MSc, Glenn Carlson, MD, et al. Published- The Lancet::November 03, 2023DOI:https://doi.org/10.1016/S0140-6736(23)02230-4.
These results support progress to Phase III, which aims to start in Q4 2023.
340 mins
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.